The real-world oral corticosteroid burden in patients starting anti-interleukin-5 therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON28832

Enrollment

350

Registered

2020-11-06

Start date

2020-10-05

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe eosinophilic astma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Included in RAPSODI, receiving anti-IL-5 treatment before 1/1/2019.

Exclusion criteria

Exclusion criteria: - Inflammatory comorbidities (Rheumatoid disease, inflammatory bowel disease or oncological disease) (based on registration in RAPSODI)

Design outcomes

Primary

Measure	Time frame
Change in cumulative OCS dose between 2 years before and 2 years after start of anti-IL-5 therapy	—

Secondary

Measure	Time frame
Course of mean OCS dose per 3 month periods, during 2 years before and after initiating anti-IL-5 treatment.	—

Contacts

Public ContactHans Kroes

Medisch Centrum Leeuwarden

hans.kroes1@znb.nl0582861837

Outcome results